Evidence map›Paper›PMID 38543974›Full record

ArticleVaccines2024

Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth.

Martin R Ramos-Gonzalez, Mohammad Tarique, Lalit Batra, Feyza Arguc, Rodolfo Garza-Morales, Haval Shirwan, Esma S Yolcu, Jorge G Gomez-Gutierrez

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Martin R Ramos-GonzalezRoy Blunt NextGen Precision Health Building, University of Missouri, Columbia, MO 65211, USA.ORCID 0000-0002-4794-0417
Mohammad TariqueRoy Blunt NextGen Precision Health Building, University of Missouri, Columbia, MO 65211, USA.
Lalit BatraRegional Biocontainment Laboratory, Center for Predictive Medicine, University of Louisville, Louisville, KY 40222, USA.ORCID 0000-0002-4375-9004
Feyza ArgucRoy Blunt NextGen Precision Health Building, University of Missouri, Columbia, MO 65211, USA.
Rodolfo Garza-MoralesDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA.ORCID 0000-0002-3613-521X
Haval ShirwanRoy Blunt NextGen Precision Health Building, University of Missouri, Columbia, MO 65211, USA.ORCID 0000-0002-1657-9470
Esma S YolcuRoy Blunt NextGen Precision Health Building, University of Missouri, Columbia, MO 65211, USA.ORCID 0000-0002-4312-8798
Jorge G Gomez-GutierrezRoy Blunt NextGen Precision Health Building, University of Missouri, Columbia, MO 65211, USA.ORCID 0000-0003-3610-260X
University of Missouri · USMayo Clinic Hospital · USUniversity of Louisville · US

Funding

Oncolytic Adenovirus Armed with SA-4-1BBL Immune Checkpoint Stimulator for Lung Cancer ImmunotherapyR21CA249348 · NCI · UNIVERSITY OF MISSOURI-COLUMBIA · PI GOMEZ-GUTIERREZ, JORGE G · 2021 to 2021
$352k
NCI NIH HHS R21 CA249348NCI NIH HHS R21CA249348
6 · The paper itself

Abstract

Natural 4-1BBL (CD137L) is a cell membrane-bound protein critical to the expansion, effector function, and survival of CD8

Indexed as

adenoviruscancerimmunotherapylungoncolyticSA-4-1BBL

Identifiers

PMID38543974
PMCPMC10974162
OpenAlexW4393039233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.